Appears On
Episode Appearances
The Top Line · Jul 10, 2026
A $10B deal, China trial scrutiny and highlights from ADA 2026
“Discussed Amgen's positioning as potential global leader in cardiometabolic risk management by 2030”
Vertex Crinetics acquisition and rare endocrine disease expansionClinical trial regulation and China data integrity scrutinyGLP-1 agonist efficacy and weight loss outcomes
View Analysis